Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitro
- PMID:19773541
- DOI: 10.1124/dmd.109.029355
Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitro
Abstract
Systemic exposure of the antidepressant S-citalopram (escitalopram, SCIT) differs several-fold according to variable cytochrome P450 2C19 activity, demonstrating the importance of this enzyme for the metabolic clearance of SCIT in vivo. However, previous studies have indicated that the involvement of CYP2C19 in formation of the metabolite N-desmethyl S-citalopram (SDCIT) is limited. Therefore, the purpose of the present in vitro study was to investigate to what extent the CYP2C19-mediated clearance of SCIT was due to a metabolic pathway different from N-desmethylation and to identify the product(s) of this possible alternative metabolic reaction. CYP2C19-mediated metabolism of SCIT was investigated using recombinant Supersomes expressing human CYP2C19. Initial experiments showed that approximately half of the CYP2C19-mediated clearance of SCIT was accounted for by the N-desmethylation pathway. Subsequent experiments identified that, in addition to SDCIT, the propionic acid metabolite of SCIT (SCIT PROP) was formed by CYP2C19 in vitro. Formation of SCIT PROP accounted for 35% of total CYP2C19-mediated clearance of SCIT (calculated as the ratio between metabolite formation rate and substrate concentration at low substrate concentration). Moreover, analysis of samples from six CYP2C19-genotyped patients treated with SCIT indicated that differences in serum concentrations of SCIT between CYP2C19 genotypes may be due to a combined effect on SCIT PROP and SDCIT formation. Identification of SCIT PROP as a metabolic pathway catalyzed by CYP2C19 might explain why impaired CYP2C19 activity has a substantially larger effect on SCIT exposure than estimated from in vitro data based solely on formation of SDCIT.
Similar articles
- O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes.Liu ZQ, Zhu B, Tan YF, Tan ZR, Wang LS, Huang SL, Shu Y, Zhou HH.Liu ZQ, et al.J Pharmacol Exp Ther. 2002 Jan;300(1):105-11. doi: 10.1124/jpet.300.1.105.J Pharmacol Exp Ther. 2002.PMID:11752104
- Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol.Beers JL, Fu D, Jackson KD.Beers JL, et al.Drug Metab Dispos. 2021 Oct;49(10):882-891. doi: 10.1124/dmd.120.000350. Epub 2021 Jul 30.Drug Metab Dispos. 2021.PMID:34330718Free PMC article.
- Pharmacological treatments in panic disorder in adults: a network meta-analysis.Guaiana G, Meader N, Barbui C, Davies SJ, Furukawa TA, Imai H, Dias S, Caldwell DM, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A, Dawson S, Robertson L.Guaiana G, et al.Cochrane Database Syst Rev. 2023 Nov 28;11(11):CD012729. doi: 10.1002/14651858.CD012729.pub3.Cochrane Database Syst Rev. 2023.PMID:38014714Free PMC article.Review.
- Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19.Yu BN, Chen GL, He N, Ouyang DS, Chen XP, Liu ZQ, Zhou HH.Yu BN, et al.Drug Metab Dispos. 2003 Oct;31(10):1255-9. doi: 10.1124/dmd.31.10.1255.Drug Metab Dispos. 2003.PMID:12975335
- Exploring conceptual and theoretical frameworks for nurse practitioner education: a scoping review protocol.Wilson R, Godfrey CM, Sears K, Medves J, Ross-White A, Lambert N.Wilson R, et al.JBI Database System Rev Implement Rep. 2015 Oct;13(10):146-55. doi: 10.11124/jbisrir-2015-2150.JBI Database System Rev Implement Rep. 2015.PMID:26571290
Cited by
- Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline.Gjestad C, Westin AA, Skogvoll E, Spigset O.Gjestad C, et al.Ther Drug Monit. 2015 Feb;37(1):90-7. doi: 10.1097/FTD.0000000000000101.Ther Drug Monit. 2015.PMID:24887634Free PMC article.
- Citalopramin vitro metabolism in a Beagle dog: A role for CYP2D15 in the production of toxic didesmethylcitalopram?Rochat B, Paus E, Maitre C, Baumann P.Rochat B, et al.Vet Med (Praha). 2023 Apr 28;68(4):135-144. doi: 10.17221/65/2022-VETMED. eCollection 2023 Apr.Vet Med (Praha). 2023.PMID:37982088Free PMC article.
- PharmGKB summary: citalopram pharmacokinetics pathway.Sangkuhl K, Klein TE, Altman RB.Sangkuhl K, et al.Pharmacogenet Genomics. 2011 Nov;21(11):769-72. doi: 10.1097/FPC.0b013e328346063f.Pharmacogenet Genomics. 2011.PMID:21546862Free PMC article.Review.No abstract available.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Molecular Biology Databases